Successful Titration of Triple Oral Therapy in a Patient with Pulmonary Arterial Hypertension (PAH)

Overview: Combination therapy has become the standard of care for patients with PAH. Therapeutic options now include PDE-5 inhibitors, endothelian-receptor antagonists and prostacyclin analogues. With the recent availability of oral prostacyclin therapy, triple therapy for PAH has become an increasingly attractive, and successful, option. Below we provide a case report of a patient treated with the successive addition of PAH therapies. Case Presentation: KD is a 42 year old female with a history of scleroderma complicated by esophageal dysmotility, interstitial lung disease, chronic respiratory failure and PAH.

Source: Journal of Cardiac Failure - August 1, 2017 Category: Cardiology Authors: Amy Clegg, Daniel Bensimhon Source Type: research